Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly becoming a Wall Street darling. Its vaccine shot brought in billions, positioning the biotech firm as a symbol of innovation and speed in a global crisis. But the post-Covid world hasn’t been as kind. With vaccination rates falling and Spikevax sales drying up, revenues have tumbled. The gold rush moment is clearly over.

Now, in a bid to stay lean, Moderna is cutting roughly 10% of its workforce as part of a broader plan to reduce annual operating expenses by $1.5 billion through 2027. The company tried to dodge layoffs by tightening R&D budgets, dialing down manufacturing, and renegotiating supplier deals. But with the market shifting and respiratory vaccine sales stalling, CEO Stéphane Bancel says it’s time to realign the business with a leaner game plan.